Patent · US Active

Fully stabilized asymmetric siRNA

US12173286B2 · kind B2 · utility

0Cited by
82References
39Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 13, 2020
Grant dateDec 24, 2024
Priority date
Expiry dateMar 27, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/53
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.